Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma.

Published

Journal Article

Drug delivery vehicles are often assessed for their ability to control primary tumor growth, but the outcome of cancer treatment depends on controlling or inhibiting metastasis. Therefore, we studied the efficacy of our genetically encoded polypeptide nanoparticle for doxorubicin delivery (CP-Dox) in the syngeneic metastatic murine models 4T1 and Lewis lung carcinoma. We found that our nanoparticle formulation increased the half-life, maximum tolerated dose, and tumor accumulation of doxorubicin. When drug treatment was combined with primary tumor resection, greater than 60% of the mice were cured in both the 4T1 and Lewis lung carcinoma models compared to 20% treated with free drug. Mechanistic studies suggest that metastasis inhibition and survival increase were achieved by preventing the dissemination of viable tumor cells from the primary tumor.

Full Text

Duke Authors

Cited Authors

  • Mastria, EM; Chen, M; McDaniel, JR; Li, X; Hyun, J; Dewhirst, MW; Chilkoti, A

Published Date

  • June 28, 2015

Published In

Volume / Issue

  • 208 /

Start / End Page

  • 52 - 58

PubMed ID

  • 25637704

Pubmed Central ID

  • 25637704

Electronic International Standard Serial Number (EISSN)

  • 1873-4995

Digital Object Identifier (DOI)

  • 10.1016/j.jconrel.2015.01.033

Language

  • eng

Conference Location

  • Netherlands